China SXT Pharmaceuticals, Inc.
SXTC · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,741 | $1,928 | $1,972 | $2,602 |
| % Growth | -9.7% | -2.2% | -24.2% | – |
| Cost of Goods Sold | $1,373 | $1,375 | $1,545 | $1,351 |
| Gross Profit | $367 | $554 | $426 | $1,252 |
| % Margin | 21.1% | 28.7% | 21.6% | 48.1% |
| R&D Expenses | $191 | $184 | $0 | $0 |
| G&A Expenses | $2,758 | $2,636 | $5,646 | $5,517 |
| SG&A Expenses | $3,048 | $3,069 | $6,034 | $6,441 |
| Sales & Mktg Exp. | $290 | $434 | $387 | $925 |
| Other Operating Expenses | -$191 | -$184 | $0 | $0 |
| Operating Expenses | $3,048 | $3,069 | $6,034 | $6,441 |
| Operating Income | -$2,680 | -$2,515 | -$5,608 | -$5,190 |
| % Margin | -154% | -130.4% | -284.4% | -199.4% |
| Other Income/Exp. Net | -$623 | -$583 | -$327 | -$218 |
| Pre-Tax Income | -$3,304 | -$3,099 | -$5,935 | -$5,408 |
| Tax Expense | $0 | $0 | $0 | $328 |
| Net Income | -$3,304 | -$3,099 | -$5,935 | -$5,736 |
| % Margin | -189.8% | -160.7% | -301% | -220.4% |
| EPS | -8.18 | -3.57 | -22.23 | -137.92 |
| % Growth | -129.1% | 83.9% | 83.9% | – |
| EPS Diluted | -8.18 | -3.57 | -22.23 | -137.92 |
| Weighted Avg Shares Out | 404 | 867 | 267 | 42 |
| Weighted Avg Shares Out Dil | 404 | 867 | 267 | 42 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $648 | $544 | $477 | $37 |
| Depreciation & Amortization | $82 | $203 | $250 | $320 |
| EBITDA | -$2,573 | -$2,351 | -$5,208 | -$5,051 |
| % Margin | -147.8% | -121.9% | -264.1% | -194.1% |